Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy

NCT07807475 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT07807475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Observational
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
September 15, 2034
Enrollment
232 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

barcelona clinic liver cancer (bclc) stage a, b or c hcc